By analyzing simple, standard, blood tests, and applying Anpac Bio's proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio's CDA technology identifies cancer with measurably-greater accuracy than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.

Comprehensive research validity data from the 50,000+ cases processed to date demonstrate CDA diagnostics consistently detect over 26+ cancers -- with a sensitivity and specificity rate range of 75%-90% -- usually identifying the disease at its earliest stages.

The company has filed over 200 CDA-related patent applications worldwide – 65+ issued currently; and maintains operations in six sites, employing over 100 people globally.

"Since our company launched in 2008, Anpac Bio has pioneered the 'liquid biopsy' space," states Dr. Yu. "Our CDA technology has been extensively tested, verified, and used daily by dozens of Asia's most well-respected and renowned medical institutions. We are also generating equally accurate and positive results in the United States. And as this research has been published and presented before respected scientific organizations, such as the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit, our CDA tests are in great demand. We're now processing CDA tests for individuals, health systems, insurance companies, educational institutions, and corporations. We're very proud that our CDA devices have advanced beyond the laboratory, and are processing real tests for real people – saving lives every day. At this rate, we project to double our CDA cases worldwide and save many more lives in 2018!"